Targeted Cancer Drugs The Launch Landscape
to 2018
Packed with statistics, competitive rankings, timelines and sector share comparisons, this report
examines the current market for targeted cancer drugs, with an overview of both products and players.
Looking ahead, the report identifies 79 new candidates that are currently under a minimum of Phase II
development for solid tumours and provides a timeline detailing estimated launch dates to 2018. There
is a review of the molecular targets on which industry attention is focused, and the companies involved
in the development and commercialisation of the products directed against these targets. Finally, each
product is considered individually in terms of its mode of action, current developmental status, clinical
data, risks associated with development, developer and potential competition within the marketplace.
Current therapeutic approaches for targeted agents will dominate...
With the success of products directed against established targets, such as ErbB (HER) and VEGF, the
search continues for new and improved agents within these groups. For example, Roche is capitalising
on the success of its HER2 inhibitor, Herceptin (trastuzumab), with the development of an antibody-drug
conjugate, trastuzumab emtansine, which consists of the monoclonal antibody, trastuzumab, linked to
the antimicrotubule agent, DM1. Pfizer has developed a multi-kinase inhibitor, dacomitinib, that targets
HER1, 2 and 4, and has shown superiority to Roche's Tarceva (erlotinib) in extending progression-free
survival in advanced non-small cell lung cancer patients. In addition, a variety of smallmolecule kinase
inhibitors that target multiple components of the VEGF pathway and/or other angiogenic pathways are
progressing through clinical trials.
Explore Comprehensive list of more than 306 Tables & Figures available in the report
Targeted Cancer Drugs Market
Report Details:
Published: February 2012
No. of Pages: 306
Price: Single User License: US$2265
Questions answered by the report
How many products are profiled treating lung, breast and colorectal cancer?
Which developmental pathways are much fancied to provide significant clinical advances and
which companies are involved?
BMS, Eli Lilly, Roche, and Takeda all have five or more products in latestage expected to launch –
what are they, what do they target and when are they expected?
What are the prospects for Teva Pharmaceutical Industries’ oncology portfolio?
Emerging opportunities: with whom are the smaller companies working and how many have yet
to secure development/marketing collaborations?
Table of Contents
Executive Summary
Targeted Cancer Therapies
What the Future Holds
Molecular Targets
Targeted cancer Therapies under development
Heat Shock Protein Inhibitors
Insulin-like Growth Factor Receptor Inhibitors
Poly-ADP-ribose Polymerase Inhibitors
Phosphoinositide 3-kinase and Akt Inhibitors
Tumour Necrosis Factor Apoptosis-inducing Ligand Agonists
Tumour Vasculature Inhibitors
Miscellaneous Novel Inhibitors
Bibliography
List of Tables
List of Charts
Request a Sample for or Inquire before buying the report @
http://www.reportsnreports.com/reports/147954-targeted-cancer-drugs-the-launch-landscape-to-
2018.html
Contact:
Priyank Tiwari
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-391-5441
sales@reportsandreports.com
Visit our Market Research Blog @ http://www.reportsnreportsblog.com/
Connect With Us: